Active Receptor Activator Of Nuclear Factor Kappa B (RANk)
CD265; TNFRSF11A; TNFRSF11-A; ODFR; OFE; TRANCER; Osteoclast differentiation factor receptor; Tumor Necrosis Factor Receptor Superfamily,Member 11a,NFKB Activator
- 物种Homo sapiens (Human，人) 相同的名称，不同的物种。
- 缓冲液成份20mM Tris, 150mM NaCl缓冲液（pH8.0, 含有1mM EDTA, 1mM DTT, 0.01% SKL, 5% Trehalose和Proclin300）
- 纯度> 97%
- 应用Cell culture; Activity Assays.
- 下载 英文说明书 中文说明书
- 规格 10µg50µg 200µg 1mg 5mg (保证有货 万一缺货 免费重做)
- 价格 ¥ 1814 ¥ 4536 ¥ 9072 ¥ 27216 ¥ 68040
- Figure. Gene Sequencing (Extract)
- Figure. SDS-PAGE
- Figure. Western Blot
- 通过ISO 9001、ISO 13485质量体系认证
Figure. The binding activity of TNFRSF11A with TRAF5.
RANK tumor necrosis factor receptor superfamily member 11A protein (TNFRSF11A) also known as receptor Activator of Nuclear Factor κ B (RANK) or TRANCE Receptoris a member of the tumor necrosis factor receptor (TNFR) molecular sub-family. TNFRSF11A is the receptor for RANK-Ligand (RANKL) and part of the RANK/RANKL/OPG signaling pathway that regulates osteoclast differentiation and activation. It is associated with bone remodeling and repair, immune cell function, lymph node development, thermal regulation, and mammary gland development. Besides, TNF Receptor Associated Factor 5 (TRAF5) has been identified as an interactor of TNFRSF11A, thus a binding ELISA assay was conducted to detect the interaction of recombinant human TNFRSF11A and recombinant human TRAF5. Briefly, TNFRSF11A were diluted serially in PBS, with 0.01% BSA (pH 7.4). Duplicate samples of 100µL were then transferred to TRAF5-coated microtiter wells and incubated for 2h at 37℃. Wells were washed with PBST and incubated for 1h with anti-TNFRSF11A pAb, then aspirated and washed 3 times. After incubation with HRP labelled secondary antibody, wells were aspirated and washed 3 times. With the addition of substrate solution, wells were incubated 15-25 minutes at 37℃. Finally, add 50µL stop solution to the wells and read at 450nm immediately. The binding activity of TNFRSF11A and TRAF5 was shown in Figure 1, and this effect was in a dose dependent manner.
Reconstitute in 20mM Tris, 150mM NaCl (PH8.0) to a concentration of 0.1-1.0 mg/mL. Do not vortex.
|编号||适用物种：Homo sapiens (Human，人)||应用(仅供研究使用，不用于临床诊断！)|
|RPC057Hu01||核因子κB受体激活因子(RANk)重组蛋白||Positive Control; Immunogen; SDS-PAGE; WB.|
|APC057Hu01||核因子κB受体激活因子(RANk)活性蛋白||Cell culture; Activity Assays.|
|PAC057Hu01||核因子κB受体激活因子(RANk)多克隆抗体||WB; IHC; ICC; IP.|
|MAC057Hu22||核因子κB受体激活因子(RANk)单克隆抗体||WB; IHC; ICC; IP.|
|MAC057Hu21||核因子κB受体激活因子(RANk)单克隆抗体||WB; IHC; ICC; IP.|
|SEC057Hu||核因子κB受体激活因子(RANk)检测试剂盒(酶联免疫吸附试验法)||Enzyme-linked immunosorbent assay for Antigen Detection.|
|European Journal of Immunology||Human polymorphonuclear neutrophils express the receptor activator of NFκB (RANK) and are activated by its ligand RANKL [Wiley: source]|
|International Journal of Cardiology||Valvular osteoclasts in calcification and aortic valve stenosis severity [PubMed: 23452891]|
|Bulletin of Experimental Biology and Medicine||Receptor Activator of Nuclear Transcription Factor NF-κB(RANK), Its Ligand RANKL, and Natural Inhibitor of RANKL Osteoprotegerin (OPG) in the Blood Serum of Patients with Primary Bone Tumors [DOI:110.1007/s10517-017-3832-9]|